P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice

Background Achieving minimal residual disease (MRD) negativity during treatment for multiple myeloma (MM) is prognostic for disease free and overall survival. There is limited testing of MRD outside clinical trials, and the need to process fresh samples for multicolour flow cytometry (MCF) assays presents a challenge to laboratories. We set up an 8-colour MCF assay, in collaboration with a reference centre (Leeds HMDS), to identify and quantify...